The treatments of Carvykti in Multiple myeloma
DOI:
https://doi.org/10.54097/hset.v36i.5646Keywords:
Clinical, Carvykti, Treatment.Abstract
Multiple myeloma is a severe malignance caused by damaged B cells from bone marrow plasma cells. Multiple treatments have been introduced to release and treat such a disease, but in general, high rate and severity of adverse events and relatively unideal efficacies of those existing treatments necessitate a new therapy achieving a better curative effect. Thus, CARVYKTI, a CAR-T therapy, has been developed for treat patients with multiple myeloma and who have already received several other treatments. By having genetically modified T cells, damaged cancer-causing B cells are targeted and vanished specifically. Recently, the FDA has officially approved CARVYKTI as a treatment for refractory multiple myeloma, and the basic pharmacology and the phase1b-2 clinical trial are summarized in this paper.
Downloads
References
Berdeja, J.G. et al. Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study, The Lancet, Volume 398, Issue 10297, Pages 314-324. (2021).
US Food and Drug Administration (2022). Summary Basis for Regulatory Action, BLA 125746/0.
Kumar, S., Rajkumar, V., Kyle, R. et al. Multiple myeloma. Nat Rev Dis Primers 3, 17046 (2017).
Wang, H., Kaur, G., Sankin, A.I. et al. Immune checkpoint blockade and CAR-T cell therapy in hematologic malignancies. J Hematol Oncol 12, 59 (2019). https://doi.org/10.1186/s13045-019-0746-1
The American Cancer Society medical and editorial content team (2021). Drug Therapy for Multiple Myeloma. https://www.cancer.org/cancer/multiple-myeloma/treating/chemotherapy.html
C. Jekimovs, E. Bolderson, A. Suraweera, M. Adams, K. J. O’Byrne, and D. J. Richard, “Chemotherapeutic compounds targeting the DNA double-strand break repair pathways: The good, the bad, and the promising,” Front. Oncol., vol. 4 APR, no. April, pp. 1–18, 2014, doi: 10.3389/fonc.2014.00086.
F. Alanazi, F. A. A. Kwa, G. Burchall, and D. E. Jackson, “New generation drugs for treatment of multiple myeloma,” Drug Discovery Today, vol. 25, no. 2. Elsevier Ltd, pp. 367–379, Feb. 01, 2020. doi: 10.1016/j.drudis.2019.11.008.
J. M. Curtsinger and M. F. Mescher, “Inflammatory cytokines as a third signal for T cell activation,” Curr. Opin. Immunol., vol. 22, no. 3, pp. 333–340, 2010, doi: 10.1016/j.coi.2010.02.013.
K. Skorka, K. Ostapinska, A. Malesa, and K. Giannopoulos, “The Application of CAR-T Cells in Haematological Malignancies,” Arch. Immunol. Ther. Exp. (Warsz)., vol. 68, no. 6, pp. 1–19, 2020, doi: 10.1007/s00005-020-00599-x.
Z. Wang, Z. Wu, Y. Liu, and W. Han, “New development in CAR-T cell therapy,” J. Hematol. Oncol., vol. 10, no. 1, pp. 1–11, 2017, doi: 10.1186/s13045-017-0423-1.
S. Manier et al., “Current state and next-generation CAR-T cells in multiple myeloma,” Blood Reviews. Churchill Livingstone, 2022. doi: 10.1016/j.blre.2022.100929.
Downloads
Published
Issue
Section
License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
How to Cite
